search
Back to results

A Study to Investigate the Safety and Immunogenicity of the SF2a-TT15 Synthetic Carbohydrate-based Conjugate Vaccine Against Shigella Flexneri 2a (GlycoShig3)

Primary Purpose

Healthy

Status
Active
Phase
Phase 2
Locations
Kenya
Study Type
Interventional
Intervention
Injection SF2A-TT15 10 µg Adjuvanted
Injection SF2A-TT15 10 µg
Injection Adjuvanted Placebo
Injection Placebo
Injection SF2A-TT15 2 µg Adjuvanted
Injection SF2A-TT15 2 µg
Sponsored by
Institut Pasteur
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Healthy focused on measuring vaccine, anti-shigella, shigella, diarrheic disease, Kenya

Eligibility Criteria

8 Months - 50 Years (Child, Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

For adults:

  1. Healthy men and women between 18 and 50 (inclusive) years of age.
  2. Subjects who provide written informed consent or thumb print in the presence of a witness to participate in the study
  3. Women willing to use at least 1 reliable method of contraception during the study period, or are surgically sterilized, and agree to undergo repeated pregnancy tests (before each vaccination) and men willing to use an effective method of contraception (e.g. condom).

For children and infants:

  1. Healthy boys and girls between 2 and 5 years of age for the children group (cohort 2)
  2. Healthy boys and girls 9 mo-old (+/- 1 month) for the infant group (cohort 3)
  3. Parents or legally acceptable representatives, as appropriate, who are willing and able to provide signed/thumb printed informed consent for children and infants.
  4. Infant and children should have a normal nutritional Z score (-2 or greater) according to the mother and child health handbook of the republic of Kenya - Ministry of Health before entering the trial.

For all:

  1. Signed/thumb written informed consent, in accordance with local practice, provided by adult volunteers (participants 18 years of age and older), parent(s) or legal representative(s) for children and infants participants as applicable, who, in the opinion of the Investigator, can and will comply with the requirements of the protocol.
  2. Subjects in general good health in the opinion of the Investigator as determined by medical history, vital signs and a physical examination.
  3. No clinically significant abnormalities in hematology, blood chemistry, or urinalysis laboratory tests at screening.
  4. Negative HIV, Hepatitis B and Hepatitis C serology tests and malaria test.

Exclusion Criteria:

  1. Subjects with a history of clinically significant gastrointestinal disorders (e.g. gastroesophageal reflux disease, peptic ulcer, celiac disease, inflammatory bowel disease).
  2. Individuals with immunosuppressive diseases or under immunosuppressive therapy.
  3. Previous participation in any study in which a Shigella-vaccine candidate was administered.
  4. Suspected or known hypersensitivity (including allergy) to any of the vaccine components or to previous vaccine, or to medicinal products or medical equipment whose use is foreseen in this study.
  5. Use of any prescription or over-the-counter (OTC) medications, within 14 days prior vaccination. Paracetamol or ibuprofen for symptomatic relief of pain is allowed until 48 hours prior to vaccination.
  6. Women who are pregnant, breast-feeding, or are of childbearing age and are not on or do not plan to use acceptable contraceptives for the duration of the study.
  7. Subjects with any significant acute medical situation (e.g. acute infection) within 48 hrs prior to study entry, in the opinion of the Principal Investigator.
  8. Participation in another clinical trial with drugs within 3 months prior first study injection.

Sites / Locations

  • KEMRI / Henry M. Jackson Foundation Medical Research International

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm 6

Arm 7

Arm 8

Arm 9

Arm 10

Arm 11

Arm 12

Arm Type

Experimental

Placebo Comparator

Experimental

Placebo Comparator

Experimental

Placebo Comparator

Experimental

Placebo Comparator

Experimental

Placebo Comparator

Experimental

Placebo Comparator

Arm Label

Adults cohort 1 vaccinees

Adults cohort 1 placebo recipients

Children cohort 2 vaccinees

Children cohort 2 placebo recipients

Infants cohort 3A vaccinees (-)

Infants cohort 3A placebo recipients (-)

Infants cohort 3A vaccinees (+)

Infants cohort 3A placebo recipients (+)

Infants cohort 3B vaccinees (-)

Infants cohort 3B placebo recipients (-)

Infants cohort 3B vaccinees (+)

Infants cohort 3B placebo recipients (+)

Arm Description

Eligible subjects (adults - 18 to 50 yr-old) will be randomized to receive 3 intramuscular (IM) injections with the 10μg OS adjuvanted dose (or matching placebo), at a ratio of 3:1.

Eligible subjects (adults - 18 to 50 yr-old) will be randomized to receive 3 IM injections with the adjuvanted matching placebo.

Eligible subjects (Children 2 to 5 yr-old) will be randomized to receive 3 IM injections of the 10 μg OS dose with Alhydrogel (or matching placebo) at a ratio of 3:1.

Eligible subjects (Children 2 to 5 yr-old) will be randomized to receive 3 IM injections of the matching placebo with Alhydrogel.

Eligible subjects (9 mo-old +/- 1mo infants) will be randomized to receive 3 IM injections of the not adjuvanted 2 μg dose (or of matching placebo), at a ratio of 4:1.

Eligible subjects (9 mo-old +/- 1mo infants) will be randomized to receive 3 IM injections of the not adjuvanted matching placebo.

Eligible subjects (9 mo-old +/- 1mo infants) will be randomized to receive 3 IM injections of the adjuvanted 2 μg dose (or of matching placebo), at a ratio of 4:1.

Eligible subjects (9 mo-old +/- 1mo infants) will be randomized to receive 3 IM injections of the adjuvanted matching placebo.

Eligible subjects (9 mo-old +/- 1mo infants) will be randomized to receive 3 IM injections of the not adjuvanted 10 μg dose (or of matching placebo), at a ratio of 4:1.

Eligible subjects (9 mo-old +/- 1mo infants) will be randomized to receive 3 IM injections of the not adjuvanted matching placebo.

Eligible subjects (9 mo-old +/- 1mo infants) will be randomized to receive 3 IM injections of the adjuvanted 10 μg dose (or of matching placebo), at a ratio of 4:1.

Eligible subjects (9 mo-old +/- 1mo infants) will be randomized to receive 3 IM injections of the adjuvanted matching placebo.

Outcomes

Primary Outcome Measures

Number, proportion,severity and relatedness of adverse events (AEs) to measure the safety and tolerability of SF2a-TT15 vaccine (2 μg OS and 10 μg OS) in each cohort.
Solicited reactions, AEs, SAEs assessed post-vaccination using targeted physical examinations, vital signs, and clinical laboratory tests
Analyses of the serum anti-S. flexneri 2a lipopolysaccharide (LPS) IgG antibody response in the infant target population to assess the immunogenicity of the vaccine.
Proportion of responders (4-fold increases over baseline) in serum anti-S. flexneri 2a LPS IgG antibody response

Secondary Outcome Measures

The number and proportion of responders, the geometric mean titer (GMT), mean fold-rises (compared to baseline), and peak-post-vaccination of the serum bactericidal activity (SBA) antibody (functionality of SF2a-specific IgGs antibodies in infants).
Proportion of responders (4-fold increases over baseline) in serum bactericidal activity (SBA) antibody
Analyses of the serum anti-S. flexneri 2a LPS Immunoglobulins G (IgG) antibody response in the adult and children cohorts.
Proportion of responders (4-fold increases over baseline) in serum anti-S. flexneri 2a LPS IgG antibody response
Comparison of the Measle-Rubella (MR) vaccine immune response in SF2a-TT15 vaccinees and placebo groups for the infant cohort.
The antibody titer to the MR vaccine will be compared between SF2a-TT15 vaccinees and placebo groups to assess whether the SF2a-TT15 Shigella vaccine candidate impacts on the immunogenicity of the MR vaccine.

Full Information

First Posted
September 24, 2020
Last Updated
September 29, 2023
Sponsor
Institut Pasteur
Collaborators
Wellcome Trust, Bill & Melinda Gates Medical Research Institute, Henry M. Jackson Foundation Medical Research International, Walter Reed Army Institute of Research (WRAIR), Parexel, ClinWin Research
search

1. Study Identification

Unique Protocol Identification Number
NCT04602975
Brief Title
A Study to Investigate the Safety and Immunogenicity of the SF2a-TT15 Synthetic Carbohydrate-based Conjugate Vaccine Against Shigella Flexneri 2a
Acronym
GlycoShig3
Official Title
A Phase 2a Age Descending Study to Investigate the Safety and Immunogenicity of the SF2a-TT15 Synthetic Carbohydrate-based Conjugate Vaccine Against Shigella Flexneri 2a in Adults, Children, and Infant Target Population in Endemic Countries.
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
October 6, 2020 (Actual)
Primary Completion Date
December 30, 2023 (Anticipated)
Study Completion Date
December 30, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Institut Pasteur
Collaborators
Wellcome Trust, Bill & Melinda Gates Medical Research Institute, Henry M. Jackson Foundation Medical Research International, Walter Reed Army Institute of Research (WRAIR), Parexel, ClinWin Research

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
A study among adults, children and infants in Kenya to determine if a new type of glycoconjugate vaccine incorporating a synthetic carbohydrate component is safe and induces immunity against Shigella.
Detailed Description
The purpose of this study is to examine the safety and immunogenicity of two doses of the parenteral synthetic carbohydrate-based conjugate vaccine against Shigella flexneri 2a (Shigella flexneri 2a-Tetanus Toxoid15 (SF2a-TT15)) adjuvanted or not with Alhydrogel in infants in an endemic country (Kenya), the target population for the vaccine, using an age-descending approach. In total, 232 participants will be enrolled in the study: 16 adults (18-50 years-old), 16 children (2-5 years-old) and 200 infants (9 months-old +/ 1 mo). The vaccine will be tested in adults first, then in children and eventually in infants in Kenya (where Shigella infection is present), based on the safety/tolerability in each group before to moving to the other. Participants will be randomly assigned to receive the study vaccine or a placebo control (same solution but without the vaccine component). The participants will have to go through all the trial procedures including the 14 visits (3 injections and 11 follow-up) during a 16 months period.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Healthy
Keywords
vaccine, anti-shigella, shigella, diarrheic disease, Kenya

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Model Description
Randomized, age descending (3 cohorts), with dose escalation in the target cohort
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Masking Description
Every team will be masked except the pharmacist and the pharmacy team on site and one dedicated personal within Sponsor team.
Allocation
Randomized
Enrollment
248 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Adults cohort 1 vaccinees
Arm Type
Experimental
Arm Description
Eligible subjects (adults - 18 to 50 yr-old) will be randomized to receive 3 intramuscular (IM) injections with the 10μg OS adjuvanted dose (or matching placebo), at a ratio of 3:1.
Arm Title
Adults cohort 1 placebo recipients
Arm Type
Placebo Comparator
Arm Description
Eligible subjects (adults - 18 to 50 yr-old) will be randomized to receive 3 IM injections with the adjuvanted matching placebo.
Arm Title
Children cohort 2 vaccinees
Arm Type
Experimental
Arm Description
Eligible subjects (Children 2 to 5 yr-old) will be randomized to receive 3 IM injections of the 10 μg OS dose with Alhydrogel (or matching placebo) at a ratio of 3:1.
Arm Title
Children cohort 2 placebo recipients
Arm Type
Placebo Comparator
Arm Description
Eligible subjects (Children 2 to 5 yr-old) will be randomized to receive 3 IM injections of the matching placebo with Alhydrogel.
Arm Title
Infants cohort 3A vaccinees (-)
Arm Type
Experimental
Arm Description
Eligible subjects (9 mo-old +/- 1mo infants) will be randomized to receive 3 IM injections of the not adjuvanted 2 μg dose (or of matching placebo), at a ratio of 4:1.
Arm Title
Infants cohort 3A placebo recipients (-)
Arm Type
Placebo Comparator
Arm Description
Eligible subjects (9 mo-old +/- 1mo infants) will be randomized to receive 3 IM injections of the not adjuvanted matching placebo.
Arm Title
Infants cohort 3A vaccinees (+)
Arm Type
Experimental
Arm Description
Eligible subjects (9 mo-old +/- 1mo infants) will be randomized to receive 3 IM injections of the adjuvanted 2 μg dose (or of matching placebo), at a ratio of 4:1.
Arm Title
Infants cohort 3A placebo recipients (+)
Arm Type
Placebo Comparator
Arm Description
Eligible subjects (9 mo-old +/- 1mo infants) will be randomized to receive 3 IM injections of the adjuvanted matching placebo.
Arm Title
Infants cohort 3B vaccinees (-)
Arm Type
Experimental
Arm Description
Eligible subjects (9 mo-old +/- 1mo infants) will be randomized to receive 3 IM injections of the not adjuvanted 10 μg dose (or of matching placebo), at a ratio of 4:1.
Arm Title
Infants cohort 3B placebo recipients (-)
Arm Type
Placebo Comparator
Arm Description
Eligible subjects (9 mo-old +/- 1mo infants) will be randomized to receive 3 IM injections of the not adjuvanted matching placebo.
Arm Title
Infants cohort 3B vaccinees (+)
Arm Type
Experimental
Arm Description
Eligible subjects (9 mo-old +/- 1mo infants) will be randomized to receive 3 IM injections of the adjuvanted 10 μg dose (or of matching placebo), at a ratio of 4:1.
Arm Title
Infants cohort 3B placebo recipients (+)
Arm Type
Placebo Comparator
Arm Description
Eligible subjects (9 mo-old +/- 1mo infants) will be randomized to receive 3 IM injections of the adjuvanted matching placebo.
Intervention Type
Biological
Intervention Name(s)
Injection SF2A-TT15 10 µg Adjuvanted
Other Intervention Name(s)
SF2A-TT15 10 µg Adjuvanted, Anti-shigella experimental vaccine (10µg with alhydrogel)
Intervention Description
Intramuscular injection of experimental vaccine (adjuvanted 10 µg)
Intervention Type
Biological
Intervention Name(s)
Injection SF2A-TT15 10 µg
Other Intervention Name(s)
SF2A-TT15 10 µg not adjuvanted, Anti-shigella experimental vaccine (10µg without alhydrogel)
Intervention Description
Intramuscular injection of experimental vaccine (not adjuvanted 10 µg)
Intervention Type
Biological
Intervention Name(s)
Injection Adjuvanted Placebo
Other Intervention Name(s)
Placebo with Alhydrogel injection
Intervention Description
Intramuscular injection of Placebo with alhydrogel
Intervention Type
Biological
Intervention Name(s)
Injection Placebo
Other Intervention Name(s)
Placebo without alhydrogel injection
Intervention Description
Intramuscular injection of the not adjuvanted Placebo
Intervention Type
Biological
Intervention Name(s)
Injection SF2A-TT15 2 µg Adjuvanted
Other Intervention Name(s)
SF2A-TT15 2 µg Adjuvanted, Anti-shigella experimental vaccine (2µg with alhydrogel)
Intervention Description
Intramuscular injection of experimental vaccine (adjuvanted 2 µg)
Intervention Type
Biological
Intervention Name(s)
Injection SF2A-TT15 2 µg
Other Intervention Name(s)
SF2A-TT15 2 µg not adjuvanted, Anti-shigella experimental vaccine (2µg without alhydrogel)
Intervention Description
Intramuscular injection of experimental vaccine (not adjuvanted 2 µg)
Primary Outcome Measure Information:
Title
Number, proportion,severity and relatedness of adverse events (AEs) to measure the safety and tolerability of SF2a-TT15 vaccine (2 μg OS and 10 μg OS) in each cohort.
Description
Solicited reactions, AEs, SAEs assessed post-vaccination using targeted physical examinations, vital signs, and clinical laboratory tests
Time Frame
15 months
Title
Analyses of the serum anti-S. flexneri 2a lipopolysaccharide (LPS) IgG antibody response in the infant target population to assess the immunogenicity of the vaccine.
Description
Proportion of responders (4-fold increases over baseline) in serum anti-S. flexneri 2a LPS IgG antibody response
Time Frame
15 months
Secondary Outcome Measure Information:
Title
The number and proportion of responders, the geometric mean titer (GMT), mean fold-rises (compared to baseline), and peak-post-vaccination of the serum bactericidal activity (SBA) antibody (functionality of SF2a-specific IgGs antibodies in infants).
Description
Proportion of responders (4-fold increases over baseline) in serum bactericidal activity (SBA) antibody
Time Frame
15 months
Title
Analyses of the serum anti-S. flexneri 2a LPS Immunoglobulins G (IgG) antibody response in the adult and children cohorts.
Description
Proportion of responders (4-fold increases over baseline) in serum anti-S. flexneri 2a LPS IgG antibody response
Time Frame
15 months
Title
Comparison of the Measle-Rubella (MR) vaccine immune response in SF2a-TT15 vaccinees and placebo groups for the infant cohort.
Description
The antibody titer to the MR vaccine will be compared between SF2a-TT15 vaccinees and placebo groups to assess whether the SF2a-TT15 Shigella vaccine candidate impacts on the immunogenicity of the MR vaccine.
Time Frame
15 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
8 Months
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: For adults: Healthy men and women between 18 and 50 (inclusive) years of age. Subjects who provide written informed consent or thumb print in the presence of a witness to participate in the study Women willing to use at least 1 reliable method of contraception during the study period, or are surgically sterilized, and agree to undergo repeated pregnancy tests (before each vaccination) and men willing to use an effective method of contraception (e.g. condom). For children and infants: Healthy boys and girls between 2 and 5 years of age for the children group (cohort 2) Healthy boys and girls 9 mo-old (+/- 1 month) for the infant group (cohort 3) Parents or legally acceptable representatives, as appropriate, who are willing and able to provide signed/thumb printed informed consent for children and infants. Infant and children should have a normal nutritional Z score (-2 or greater) according to the mother and child health handbook of the republic of Kenya - Ministry of Health before entering the trial. For all: Signed/thumb written informed consent, in accordance with local practice, provided by adult volunteers (participants 18 years of age and older), parent(s) or legal representative(s) for children and infants participants as applicable, who, in the opinion of the Investigator, can and will comply with the requirements of the protocol. Subjects in general good health in the opinion of the Investigator as determined by medical history, vital signs and a physical examination. No clinically significant abnormalities in hematology, blood chemistry, or urinalysis laboratory tests at screening. Negative HIV, Hepatitis B and Hepatitis C serology tests and malaria test. Exclusion Criteria: Subjects with a history of clinically significant gastrointestinal disorders (e.g. gastroesophageal reflux disease, peptic ulcer, celiac disease, inflammatory bowel disease). Individuals with immunosuppressive diseases or under immunosuppressive therapy. Previous participation in any study in which a Shigella-vaccine candidate was administered. Suspected or known hypersensitivity (including allergy) to any of the vaccine components or to previous vaccine, or to medicinal products or medical equipment whose use is foreseen in this study. Use of any prescription or over-the-counter (OTC) medications, within 14 days prior vaccination. Paracetamol or ibuprofen for symptomatic relief of pain is allowed until 48 hours prior to vaccination. Women who are pregnant, breast-feeding, or are of childbearing age and are not on or do not plan to use acceptable contraceptives for the duration of the study. Subjects with any significant acute medical situation (e.g. acute infection) within 48 hrs prior to study entry, in the opinion of the Principal Investigator. Participation in another clinical trial with drugs within 3 months prior first study injection.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Armelle Phalipon, PhD
Organizational Affiliation
Institut Pasteur
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Laurence Mulard, PhD
Organizational Affiliation
Institut Pasteur
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Christiane Gerke, PhD
Organizational Affiliation
Institut Pasteur (Consulting)
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Fredrick Sawe, MBChB MMED
Organizational Affiliation
Kenya Medical Research Institute
Official's Role
Principal Investigator
Facility Information:
Facility Name
KEMRI / Henry M. Jackson Foundation Medical Research International
City
Kericho
Country
Kenya

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
This study is a part of a development program, Data will stay confidential and possibly shared only with program partners.

Learn more about this trial

A Study to Investigate the Safety and Immunogenicity of the SF2a-TT15 Synthetic Carbohydrate-based Conjugate Vaccine Against Shigella Flexneri 2a

We'll reach out to this number within 24 hrs